Altimmune (ALT) will host an investor webcast on Thursday, June 26, 2025 at 8:30 am E.T. to present topline 24 week data from its IMPACT Phase 2b trial evaluating pemvidutide in the treatment of patients with metabolic dysfunction-associated steatohepatitis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALT:
- Nucor, Charter, Senseonics, Shake Shack, Altimmune: Trending by Analysts
- Altimmune management to meet virtually with B. Riley
- Altimmune announces initiation of RECLAIM Phase 2 trial on pemvidutide
- Altimmune’s Earnings Call: NASH Trial & Financial Moves
- Altimmune’s Strategic Advancements and Promising Clinical Trials Justify Buy Rating